[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The Florey Institute of Neuroscience and Mental Health\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":79},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100594442","young-stroke-service-deep-phenotyping-exploring-recovery-in-young-adult-survivors-of-stroke-100594442",false,"NCT07019493","Young Stroke Service Deep Phenotyping: Exploring Recovery in Young Adult Survivors of Stroke","Inclusion Criteria:\n\n1. Between 18 and 55 years.\n2. Within one month of acute stroke confirmed with standard of care brain imaging or clinical diagnosis or for those for whom recruitment \\\u003C1 month of stroke is not possible they may be recruited to participate within 3-months of stroke\n\nExclusion Criteria:\n\n1. Severe, intercurrent or progressive illness likely to EITHER\n\n   1. Have a prognosis for survival under 24 months; OR\n   2. In the opinion of the investigator will mask the importance to the individual participant data (e.g. severe MS, dementia, etc)\n2. Major psychiatric condition requiring medical intervention","ALL","18 Years","55 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The Investigators are running a small, early-phase research study across several hospitals in Melbourne, Australia. The study will involve up to 100 young adults between the ages of 18 and 55 who have had a stroke. The goal is to test how practical it is to carry out a detailed health assessment process-called \"deep phenotyping\"-with this group.\n\nThis process involves collecting a wide range of information and samples from stroke survivors to better understand each participant's condition. The Investigators will look at how well this approach works in practice, including how easy it is to use, whether it's done consistently, and how acceptable it is to participants.\n\nAt the same time, the Investigators will also explore how different factors-such as biological markers (biomarkers), age, sex, type of stroke, lifestyle, and environment-might be related to stroke recovery. This pilot study will prepare for larger studies in the future.",[24,25,26,27],"Stroke Patients","Stroke","Stroke; Sequelae","Young Adults",[29,30,31,32,33,34,35,36],"recovery","young stroke","ischemic stroke","hemorrhagic stroke","poststroke fatigue","post-stroke cognitive impairment","function","mood","RECRUITING","2026-04-16",{"date":40,"type":41},"2026-04-21","ACTUAL",{"date":43,"type":41},"2025-07-19",{"date":45,"type":20},"2027-12",{"name":47,"class":48},"The Florey Institute of Neuroscience and Mental Health","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100467180","phase-2-safety-and-tolerability-of-adjunctive-tbo-309-in-reperfusion-for-stroke-100467180","NCT05363397","Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke","STARS","Inclusion Criteria\n\n1. Patient aged 18 years or more\n2. Patient has an acute ischaemic stroke\n3. Patient will be treated with either:\n\n   1. Intravenous thrombolysis (IVT) with alteplase or tenecteplase for a diagnosis of AIS that is confirmed by CT imaging;\n\n      alone\u002FOR WITH\n   2. Endovascular Thrombectomy (EVT) for large vessel occlusion (LVO) in the internal carotid artery, middle cerebral artery (M1 segment), middle cerebral artery (M2 segment) or with tandem occlusion of both the cervical carotid and intracranial large arteries who either:\n\n   i. presented within 6 hours of stroke onset\n\n   OR\n\n   ii. presented between 6-24 hours after they were last known to be well and clinical observations and either CT perfusion or MRI features indicate the presence of salvageable brain tissue, defined as ischaemic core \\\u003C70mL with a mismatch ratio \\>1.8 and absolute mismatch \\>15mL.\n4. Patient has at least a mild grade of neurological impairment i.e. NIHSS of 5 or more\n5. Patient has an estimated pre-stroke mRS of less than 4\n\nExclusion Criteria\n\n1. Patient is considered unlikely to benefit from study intervention defined by one of the following:\n\n   1. Advanced dementia\n   2. Severe pre-stroke disability (mRS score 4-5)\n   3. Glasgow Coma Score (GCS) 3 to 5\n   4. Evidence of a large well-defined ischaemic lesion measuring more than one third of the MCA territory\n2. High likelihood of undergoing stent insertion and requiring additional antithrombotic(s)\n3. Uncontrolled hypertension (SBP \\>180 or DBP \\>110, refractory to medical therapy)\n4. ICH within the last 90 days\n5. Myocardial infarction or stroke within the last 30 days\n6. Patient has an underlying disease process with a life expectancy of \\\u003C90 days\n7. Contraindication to thrombolysis i.e. increased bleeding risk\n8. Contraindication to intravenous contrast agents including renal impairment or allergy\n9. Known treatment with dual antiplatelet therapy or anticoagulant medication\n10. Known severe liver disease\n11. Known bleeding disorder\n12. Cardiopulmonary resuscitation or arterial puncture at non-compressible site or lumbar puncture within 7 days\n13. Another medical illness or social circumstance that may interfere with outcome assessments and follow-up\n14. Known or suspected pregnancy\n15. Patients currently participating in another interventional clinical trial\n16. Informed consent unable to be obtained from the patient or their Person Responsible\u002FMedical Treatment Decision Maker prior to study interventions\n17. Study drug cannot be given within one hour of thrombolytic drug bolus",{"count":57,"type":20},80,"INTERVENTIONAL",[60],"PHASE2","STARS is a prospective, multicentre, open-label, dose escalation, Phase IIa study to assess the safety and tolerability of TBO-309, an adjuvant antiplatelet therapy, in patients with AIS.\n\nAcute ischaemic stroke (AIS) is caused by a severe blockage of an artery leading to immediate reduced blood flow to part of the brain. Standard therapies target the blocked artery by either dissolving the blockage or removing the blockage. However, even after successful treatment, re-blockage of arteries can occur. The use of an antiplatelet therapy, TBO-309, in addition to standard therapies offers the possibility of improved restoration of blood flow and reduced rates of artery re-blockage.",[63],"Acute Ischemic Stroke",[65,25,66,67,68,69],"Antiplatelet therapy","Blood clot","Intravenous thrombolysis (IVT)","Endovascular Thrombectomy (EVT)","TBO-309","2025-11-24",{"date":72,"type":41},"2025-12-01",{"date":74,"type":41},"2023-09-27",{"date":76,"type":20},"2026-05-01",{"name":47,"class":48},7,""]